Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Revance to Participate in the Stifel 2022 Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
From Revance Therapeutics, Inc.
Via Business Wire
NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by... 
Via SBWire
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.